Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Current biodefense vaccine programs and challenges.

Wolfe DN, Florence W, Bryant P.

Hum Vaccin Immunother. 2013 Jul;9(7):1591-7. doi: 10.4161/hv.24063. Epub 2013 Feb 21.

PMID:
23428906
2.

Biological and chemical agents: a brief synopsis.

Rosenbloom M, Leikin JB, Vogel SN, Chaudry ZA.

Am J Ther. 2002 Jan-Feb;9(1):5-14. Review.

PMID:
11782813
3.

Advances in the development of next-generation anthrax vaccines.

Friedlander AM, Little SF.

Vaccine. 2009 Nov 5;27 Suppl 4:D28-32. doi: 10.1016/j.vaccine.2009.08.102. Review.

PMID:
19837282
4.

Advances in medical biological defense technology.

Culpepper RC, Pratt WD.

Clin Lab Med. 2001 Sep;21(3):679-89. Review.

PMID:
11572146
5.

Clostridium perfringens vaccines.

Titball RW.

Vaccine. 2009 Nov 5;27 Suppl 4:D44-7. doi: 10.1016/j.vaccine.2009.07.047. Review.

PMID:
19837285
6.

Technical transformation of biodefense vaccines.

Lu S, Wang S.

Vaccine. 2009 Nov 5;27 Suppl 4:D8-D15. doi: 10.1016/j.vaccine.2009.08.055. Review.

7.

Francisella tularensis vaccines.

Oyston PC.

Vaccine. 2009 Nov 5;27 Suppl 4:D48-51. doi: 10.1016/j.vaccine.2009.07.090. Review.

PMID:
19837286
8.

Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology.

Middlebrook JL.

Adv Drug Deliv Rev. 2005 Jun 17;57(9):1415-23. Review.

PMID:
15896873
9.

Defending against viruses in biowarfare. How to respond to smallpox, encephalitides, hemorrhagic fevers.

Straight TM, Lazarus AA, Decker CF.

Postgrad Med. 2002 Aug;112(2):75-6, 79-80, 85-6. Review.

PMID:
12198755
10.

[New challenges in the biological weapons convention].

Sissonen S, Raijas T, Haikala O, Hietala H, Virri M, Nikkari S.

Duodecim. 2012;128(3):283-9. Review. Finnish.

PMID:
22428382
11.

Development pathway for biodefense vaccines.

Barrett AD, Beasley DW.

Vaccine. 2009 Nov 5;27 Suppl 4:D2-7. doi: 10.1016/j.vaccine.2009.07.094. Review.

PMID:
19837280
12.

Alphavirus antiviral drug development: scientific gap analysis and prospective research areas.

Reichert E, Clase A, Bacetty A, Larsen J.

Biosecur Bioterror. 2009 Dec;7(4):413-27. doi: 10.1089/bsp.2009.0032. Review.

PMID:
20028250
13.

Particulate delivery systems for biodefense subunit vaccines.

Bramwell VW, Eyles JE, Oya Alpar H.

Adv Drug Deliv Rev. 2005 Jun 17;57(9):1247-65. Epub 2005 Apr 18. Review.

PMID:
15935873
14.

Viral vectors for use in the development of biodefense vaccines.

Lee JS, Hadjipanayis AG, Parker MD.

Adv Drug Deliv Rev. 2005 Jun 17;57(9):1293-314. Epub 2005 Apr 15. Review.

PMID:
15935875
15.

[Biological weapons. II. Smallpox, botulinum toxin, hemorrhagic fever viruses].

Christ W, Stein H.

Med Monatsschr Pharm. 2003 Jan;26(1):13-22. Review. German. No abstract available.

PMID:
12577792
16.

Deterrence of biological and chemical warfare: a review of policy options.

Lebeda FJ.

Mil Med. 1997 Mar;162(3):156-61. Review.

PMID:
9121658
17.

Cutaneous manifestations of biological warfare and related threat agents.

McGovern TW, Christopher GW, Eitzen EM.

Arch Dermatol. 1999 Mar;135(3):311-22. Review.

PMID:
10086453
18.

Anthrax vaccine. Model of a response to the biologic warfare threat.

Nass M.

Infect Dis Clin North Am. 1999 Mar;13(1):187-208, viii. Review.

PMID:
10198799
19.

Botulism and vaccines for its prevention.

Smith LA.

Vaccine. 2009 Nov 5;27 Suppl 4:D33-9. doi: 10.1016/j.vaccine.2009.08.059. Review.

PMID:
19837283
20.

[Viral hemorrhagic fever as a biological weapon].

Robenshtok E, Laster M, Katz L, Brenner B, Sagi R.

Harefuah. 2002 May;141 Spec No:96-9, 119. Review. Hebrew. Erratum in: Harefuah. 2003 Nov;142(11):801.

PMID:
12170564

Supplemental Content

Support Center